Kaplan‐Meier analysis demonstrated that DLX5 hypermethylated cases had shorter OS time than DLX5 nonhypermethylated cases among total AML, non‐M3 AML, and CN‐AML patients (P = .002, .024, and .003; Figure 4A‐C). This evidence concerns the gene DLX5 and acute myeloid leukemia.